Phase 2 Clinical Study

Study on Treatment for Relapsed and Refractory Multiple Myeloma

Evaluating an investigational medication combination to understand its effectiveness and safety for adults with multiple myeloma. Join us in advancing potential new care options.

See if you qualify Learn how it works

Sponsored by Sanofi | Trusted by thousands of participants

Enrolling Now

Study Overview

ConditionMultiple Myeloma
Duration~12 Months Treatment
EligibilityAdults with relapsed/refractory MM

About the Study

Treatment for Relapsed and Refractory Multiple Myeloma

This study investigates the use of an investigational medication in combination with other treatments for adults with relapsed and/or refractory multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow.

The purpose of this study is to evaluate the overall response rate of the investigational medication when given with other treatments. The study aims to understand how effective and safe this combination is for participants.

What to Expect

Screening PeriodUp to 28 days to determine study eligibility.
Treatment Period12 months of study treatment, organized in 28-day cycles.
End of Treatment & Follow-upA visit 30 days after the last dose, followed by long-term monitoring.

Study Eligibility Criteria

Please review the following guidelines to see if this clinical study might be a good fit for your current health situation.

You may qualify if:

You have a confirmed diagnosis of Multiple Myeloma.
Your disease can be measured through specific blood or urine tests.
Your Multiple Myeloma has returned or did not respond to past treatments (having had 1 to 3 prior treatments).
You agree to use approved birth control methods or practice abstinence during and after the study.
You are able to understand and sign the informed consent form.

You may not qualify if:

Your Multiple Myeloma has never responded to any previous treatment.
You received anti-CD38 treatment within the last 6 months, or had a bad reaction to it.
Your cancer did not respond to the medication carfilzomib.
You have a known allergy to captisol.

Not sure if you qualify?

Take our quick, secure eligibility quiz to find out if you can participate in this study.

Study Benefits & Support

As a participant in this multiple myeloma clinical study, you will receive comprehensive medical care and support throughout your journey.

Your safety, privacy, and well-being are our top priorities during the 12-month treatment period and follow-up.

Study Medication

Access to the investigational medication and other study-required treatments provided at no cost to you.

Health Monitoring

Regular health evaluations, medical exams, and close monitoring during the screening, treatment, and follow-up phases.

Specialized Care

Dedicated care and attention from a team of doctors and healthcare professionals experienced in multiple myeloma.

Advance Research

Contribute to vital medical research that helps evaluate new potential treatment combinations for future patients.

Study Information

Frequently Asked Questions

We understand that joining a clinical trial is a significant decision. Here are answers to common questions about this Phase 2 Multiple Myeloma study.

What is a clinical trial and is it safe?

A clinical trial is a research study that helps determine if an investigational medication is safe and effective. This Phase 2 study, sponsored by Sanofi, is carefully monitored by medical professionals and independent review boards to prioritize your safety and well-being at every step of the process.

How long will I be in the study?

Your participation timeline includes several phases: a screening period of up to 28 days, a study treatment period of up to 12 months (administered in 28-day cycles), an end-of-treatment visit approximately 30 days after your last dose, and a long-term follow-up period to monitor your ongoing health.

What are the possible risks and side effects?

Like all medical treatments, investigational medications may have side effects. Because this study involves treatments for relapsed and/or refractory multiple myeloma, the study doctor will provide a detailed document called the Informed Consent Form. This will thoroughly explain all known potential risks, side effects, and benefits before you make any decision to participate.

Will my information be kept confidential?

Yes. Your privacy is strictly protected. All personal and medical information collected during the study is kept highly confidential, stored securely, and complies with all local privacy regulations and clinical research standards. Your identity will never be revealed in any study reports or publications.

Can I leave the study if I change my mind?

Absolutely. Your participation is entirely voluntary. You have the right to leave the study at any time, for any reason, without any penalty. Choosing to leave will not affect your regular medical care or your relationship with your current healthcare providers.

Will I receive the actual medication or a placebo?

This study investigates an investigational medication in combination with other treatments. The specific treatment groups, and whether a placebo is used as a comparison, will be clearly explained to you by the study team during the informed consent process so you know exactly what to expect.

What happens after the study ends?

After your treatment period concludes, you will return to the study site for an end-of-treatment visit about 30 days after your last dose. Following this, you will enter a study follow-up period. This allows the medical team to continue monitoring your health, safety, and progress over time.